Project lightspeed
A case study in research ethics and accelerated vaccine development
Bibliographic Data
| ID | 21787643 |
|---|---|
| Authors | Klaus Leisinger (Global Values Alliance, Switzerland), Doris Schroeder (0000-0002-3633-2758, University of Lancashire, corresponding author) |
| Year | 2024 |
| Volume | 20 |
| Issue | 4 |
| Pages | 847-856 |
| Publication date | 2024-10-01 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Research Ethics (JOURNAL) |
| Journal identifiers | ISSN: 1747-0161 • E-ISSN: 2047-6094 |
| Publisher | SAGE Publications (PUBLISHER • US) |
| DOI | 10.1177/17470161241251597 |
| OpenAlex | W4396530198 |
| Language | EN |
| Citations received | 1 |
| References cited | 11 |
The COVID-19 pathogen led to a fast expanding pandemic because it proved lethal in certain populations but could be transmitted by persons who appeared healthy. As a result, researchers came under unprecedented time pressure to develop a vaccine. This case study focuses on the first COVID-19 vaccine, which was approved for use in humans, known as Comirnaty, the BioNTech-Pfizer COVID-19 vaccine or Vaccine BNT162b2. With the benefit of hindsight, we show how close collaboration with regulators and trust-based decisions meant that the race for a COVID-19 vaccine was won without purposefully infecting healthy participants with an infectious agent that can cause severe illness or death and for which no rescue therapy had existed
2019-20 coronavirus outbreak · Family medicine · Hindsight bias · Outbreak · Pandemic · Pathology · Medicine · Psychology · Psychology of Moral and Emotional Judgment · SARS-CoV-2 and COVID-19 Research · Vaccine Coverage and Hesitancy · Virology
| Unique citing works | 1 |
|---|---|
| Citations per year | 1 |
| Citation span | 2026 - 2026 (1) |
| Citation velocity | current |
| Highly cited | No |
| Citation types | Neutral: 1 |